• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Helix BioMedix Inc

  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Disease Focus
    • DNA Damage Response (DDR)
    • Xeroderma Pigmentosum
  • Programs
    • Pharma
    • Personal Care
  • News
    • Press Releases
    • Presentations
    • Scientific Publications
  • Investors
    • Stock Information
    • IR Updates
    • Proxy
    • Corporate Governance
  • Contact Page
You are here: Home / News / Press Releases

Press Releases

The press releases contained in this section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Helix BioMedix has no obligation to update any information contained in such press releases after the date of their issuance. For current information about the Company, please refer to our most recent public filings with the Securities and Exchange Commission.

July 10, 2017
Helix BioMedix Promotes Robin L. Carmichael to Chief Executive Officer
R. Stephen Beatty is appointed to Chief Investor Officer and Executive Chairman of the Board

Primary Sidebar

Footer

COMPANY PROFILE

Helix BioMedix is a biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum.  Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the body’s innate immunity.

 

 

 

 

Terms & Conditions | Privacy Policy

Search

 

©2023 HELIX BIOMEDIX, INC.
ALL RIGHTS RESERVED

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Copyright © 2025 · Executive Pro On Genesis Framework · WordPress · Log in